Durability and long-term outcomes of biologic therapies in psoriasis

References

• Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereology. 2017;31(2):205–212. doi: 10.1111/jdv.13854 Blackwell Publishing Ltd
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DPM, Griffiths CEM, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. doi: 10.1038/jid.2012.339
   PubMed Web of Science ®Google Scholar
• Ben Abdallah H, Johansen C, Iversen L. Key signaling pathways in psoriasis: recent insights from antipsoriatic therapeutics. Psoriasis: Targets Ther. 2021;11:83–97.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Pathophysiology RC. Clinical presentation, and treatment of psoriasis: a review. JAMA - J Am Med Assoc. 2020;323(19):1945–1960. doi: 10.1001/jama.2020.4006
   PubMed Web of Science ®Google Scholar
• Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci MDPI AG. 2019;20(6):1475. doi: 10.3390/ijms20061475.
   PubMed Web of Science ®Google Scholar
• Veysey E. Biologics for psoriasis: what does drug survival tell us? Br J Dermatol. 2020;183(2):204–205. doi: 10.1111/bjd.19189
   PubMed Web of Science ®Google Scholar
• van Muijen ME, Thomas SE, Groenewoud HMM, et al. Direct Comparison of real-world effectiveness of biologics for psoriasis using absolute and relative psoriasis Area and Severity index scores in a prospective multicentre cohort. Acta Derm Venereol. 2022;102. doi: 10.2340/actadv.v102.206.
   Web of Science ®Google Scholar
• Mason KJ, Barker J, Smith C, et al. Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatol. 2018;154(5):581–588. doi: 10.1001/jamadermatol.2018.0183
   PubMed Web of Science ®Google Scholar
• Pogácsás L, Borsi A, Takács P, et al. Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in hungary. J Dermatological Treat. 2017;28(7):635–641. doi: 10.1080/09546634.2017.1329504
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L, Vender R, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–579. doi: 10.1007/s40257-021-00598-4
   PubMed Web of Science ®Google Scholar
• van den Reek JMPA, Kievit W, Gniadecki R, et al. Drug survival studies in Dermatology: Principles, purposes, and pitfalls. J Invest Dermatol. 2015;135:1–5. doi: 10.1038/jid.2015.171
   PubMed Web of Science ®Google Scholar
• van den Reek JMPA, Kievit W, de Jong EMGJ. Comment on “drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis”. Actas Dermo-Sifiliográficas. 2017;108(7):695–696. doi: 10.1016/j.ad.2017.03.012
   PubMedGoogle Scholar
• Humira - Adalimumab. European Medicines Agency (EMA). 2020.
   Google Scholar
• Enbrel - Etanercept. European Medicines Agency (EMA). 2014.
   Google Scholar
• Remicade - Infliximab. European Medicines Agency (EMA). 2018.
   Google Scholar
• Cimzia - Certolizumab pegol. European Medicines Agency (EMA). 2022.
   Google Scholar
• Ruda RC, Kelly KA, Feldman SR. Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis. J Dermatological Treat. 2023;34(1): Taylor and Francis Ltd. doi: 10.1080/09546634.2022.2140569
   PubMed Web of Science ®Google Scholar
• Barker J, Girolomoni G, Egeberg A, et al. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. J Dermatological Treat Taylor And Francis Ltd. 2020;31(8):794–800. doi: 10.1080/09546634.2019.1610553
   PubMed Web of Science ®Google Scholar
• Svedbom A, Ståhle M. Real-world comparative effectiveness of adalimumab, etanercept and methotrexate: a Swedish register analysis. J Eur Acad Dermatol Venereol. 2020;34(3):525–532. doi: 10.1111/jdv.15978
   PubMed Web of Science ®Google Scholar
• Bellinato F, Gisondi P, Mason E, et al. Real-life effectiveness of adalimumab biosimilars in patients with chronic plaque psoriasis. Dermatol Ther (Heidelb). 2022;12(6):1303–1311. doi: 10.1007/s13555-022-00732-y
   PubMed Web of Science ®Google Scholar
• Onsun N, Güneş B, Yabacı A. Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: the real-world experience of a single center. Dermatol Ther. 2021;34(1). doi: 10.1111/dth.14623
   PubMed Web of Science ®Google Scholar
• Elberdín L, Fernández-Torres RM, Paradela S, et al. Biologic therapy for moderate to severe psoriasis. Real-world follow-up of patients who Initiated biologic therapy at least 10 years ago. Dermatol Ther (Heidelb). 2022;12(3):761–770. doi: 10.1007/s13555-022-00693-2
   PubMed Web of Science ®Google Scholar
• Kojanova M, Cetkovska P, Strosova D, et al. Real-world evidence from more than 1000 patients treated with adalimumab for moderate-to-severe psoriasis in the Czech Republic. Dermatol Ther (Heidelb). 2021;11(2):543–553. doi: 10.1007/s13555-021-00499-8
   PubMed Web of Science ®Google Scholar
• Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience. Ther Adv chronic dis. 2018;9(8):147–158. doi:10.1177/2040622318772705. Epub 2018 May 22. PMID: 30065812; PMCID: PMC6052502.
   PubMed Web of Science ®Google Scholar
• Lõpez-Ferrer A, Vilarrasa E, Gich IJ, et al. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. Br J Dermatol. 2013;169(5):1141–1147. doi: 10.1111/bjd.12543
   PubMed Web of Science ®Google Scholar
• Di Lernia V, Bianchi L, Guerriero C, et al. Adalimumab in severe plaque psoriasis of childhood: a multi-center, retrospective real-life study up to 52 weeks observation. Dermatol Ther. 2019;32(6):32. doi: 10.1111/dth.13091
   Web of Science ®Google Scholar
• Turkmen M, Dogan S. Certolizumab pegol in the treatment of psoriasis: real-life data. Dermatol Ther. 2021;34(3). doi: 10.1111/dth.14929
   PubMed Web of Science ®Google Scholar
• Dattola A, Cannizzaro MV, Mazzeo M, et al. Certolizumab pegol in the treatment of psoriasis and psoriatic arthritis: preliminary real-life data. Dermatol Ther (Heidelb). 2017;7(4):485–492. doi: 10.1007/s13555-017-0208-z
   PubMed Web of Science ®Google Scholar
• No DJ, Inkeles MS, Amin M, et al. Drug survival of biologic treatments in psoriasis: a systematic review. J Dermatological Treat Taylor And Francis Ltd. 2018;29(5):460–466. doi: 10.1080/09546634.2017.1398393
   PubMed Web of Science ®Google Scholar
• Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8(1). doi: 10.1038/s41598-018-34293-y
   Google Scholar
• Costanzo A, Malara G, Pelucchi C, et al. Effectiveness end points in real-world studies on biological therapies in psoriasis: systematic review with focus on drug survival. Dermatology. 2018;234(1–2):1–12. doi: 10.1159/000488586. Epub 2018 May 15. PMID: 30300876.
   Google Scholar
• Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–519. doi: 10.1111/bjd.16102
   PubMed Web of Science ®Google Scholar
• Mashor M, Wong KW, Tey KE, et al. A retrospective study on drug survival of biologic among patients with psoriasis seen in tertiary hospital in Johor Malaysia. Med J Malaysia. 2022;77(6):689–695. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/36448386
   PubMedGoogle Scholar
• Chatzimichail G, Günther J, Ständer S, et al. Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study. J Dermatological Treat. 2022;33(3):1749–1753. doi: 10.1080/09546634.2020.1854428
   PubMed Web of Science ®Google Scholar
• Roche H, Bouiller K, Puzenat E, et al. Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department. J Dermatological Treat. 2019;30(6):540–544. doi: 10.1080/09546634.2018.1480746
   PubMed Web of Science ®Google Scholar
• Lunder T, Marko P, Koser Kolar N, et al. Drug survival of biologic therapies for the treatment of psoriasis: results of Slovenian national registry. Biologicals. 2018;54:44–49. doi: 10.1016/j.biologicals.2018.04.003
   PubMed Web of Science ®Google Scholar
• Yayli S, Baykal Selcuk L, Aksu Arica D, et al. Drug survival of biologic treatments in Turkish patients with psoriasis. Dermatol Ther. 2020;33(6): doi: 10.1111/dth.13917
   Web of Science ®Google Scholar
• Gniadecki R, Bang B, Bryld LE, et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244–252. doi: 10.1111/bjd.13343
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Becher G, Kirby B, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131–1141. doi: 10.1001/jamadermatol.2022.2909
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Shi N, Murage M, et al. Long-term treatment patterns among patients with psoriasis treated with ixekizumab or adalimumab: a real-world study. J Drugs Dermatol. 2022;21(4):399–407. InternetAvailable from. doi: 10.36849/JDD.6336
   PubMed Web of Science ®Google Scholar
• Campanati A, Diotallevi F, Martina E, et al. Safety update of etanercept treatment for moderate to severe plaque psoriasis. Expert Opin Drug Saf. 2020;19(4):439–448. doi: 10.1080/14740338.2020.1740204
   PubMed Web of Science ®Google Scholar
• Subedi S, Gong Y, Chen Y, et al. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events. Drug Des Devel Ther. 2019. p. 2491–2502. Dove Medical Press Ltd
   PubMed Web of Science ®Google Scholar
• Kishimoto M, Komine M, Kamiya K, et al. Drug survival of tumor necrosis factor-alpha inhibitors and switched subsequent biologic agents in patients with psoriasis: a retrospective study. Dermatol Ther (Heidelb). 2023;13(6):1347–1360. doi: 10.1007/s13555-023-00932-0
   PubMed Web of Science ®Google Scholar
• Vender RB, Lynde CW. Certolizumab pegol use in the treatment of moderate-to-severe psoriasis: Real-world data from two Canadian centers. J Cutan Med Surg. 2022;26(3):267–273. InternetAvailable from. doi: 10.1177/12034754221078203
   PubMed Web of Science ®Google Scholar
• Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170(2):261–273. doi: 10.1111/bjd.12654
   PubMed Web of Science ®Google Scholar
• Levin EC, Gupta R, Brown G, et al. Biologic fatigue in psoriasis. J Dermatological Treat. 2014;25(1):78–82. doi: 10.3109/09546634.2013.826341
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–1374. doi: 10.1016/S0140-6736(05)67566-6
   PubMed Web of Science ®Google Scholar
• Stelara - Ustekinumab. European Medicines Agency (EMA). 2020.
   Google Scholar
• Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535–545. doi: 10.4161/mabs.3.6.17815
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Silvaggio D, et al. Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. Expert Opin Biol Ther. 2020;20(1):95–104. doi: 10.1080/14712598.2020.1684472
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148–1158. doi: 10.1111/jdv.13611
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183(2):294–302. doi: 10.1111/bjd.18981
   PubMed Web of Science ®Google Scholar
• Verma L, Mayba JN, Gooderham MJ, et al. Persistency of biologic therapies for plaque psoriasis in 2 large community practices. J Cutan Med Surg. 2018;22(1):38–43. doi: 10.1177/1203475417733957
   PubMed Web of Science ®Google Scholar
• Schmitt-Egenolf M, Freilich J, Stelmaszuk-Zadykowicz NM, et al. Drug persistence of biologic treatments in psoriasis: a Swedish national population study. Dermatol Ther (Heidelb). 2021;11(6):2107–2121. doi: 10.1007/s13555-021-00616-7
   PubMed Web of Science ®Google Scholar
• Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, et al. Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: real-world practice. Dermatol Ther. 2020;33(6): doi: 10.1111/dth.14202
   Web of Science ®Google Scholar
• Mahlich J, Alba A, El HL, et al. Drug survival of biological therapies for psoriasis treatment in Germany and associated costs: a retrospective claims database analysis. Adv Ther. 2019;36(7):1684–1699. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/31102203
   PubMed Web of Science ®Google Scholar
• Kishimoto M, Komine M, Kamiya K, et al. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020;47(1):33–40. doi: 10.1111/1346-8138.15146
   PubMed Web of Science ®Google Scholar
• Youn SW, Yu DY, Kim BS, et al. Clinical outcomes in adult patients with plaque psoriasis treated with ustekinumab under real-world practice in Korea: a prospective, observational, multi-center, postmarketing surveillance study. J Dermatol. 2021;48(6):778–785. doi: 10.1111/1346-8138.15670
   PubMed Web of Science ®Google Scholar
• Marinas JEC, Kim WB, Shahbaz A, et al. Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: a Canadian multicentre retrospective study. Australas J Dermatol. 2018;59(1):e11–e14. doi: 10.1111/ajd.12548
   PubMed Web of Science ®Google Scholar
• Richter L, Vujic I, Sesti A, et al. Etanercept, Adalimumab und Ustekinumab bei Psoriasis: Analyse von 209 Behandlungsreihen in Österreich. JDDG - J Ger Soc Dermatol. 2017;15:309–317. doi: 10.1111/ddg.13191
   Web of Science ®Google Scholar
• Gooderham MJ, Lynde C, Turchin I, et al. Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis. The Journal Of Dermatology. 2021;49(1):95–105. doi: 10.1111/1346-8138.16214
   PubMed Web of Science ®Google Scholar
• Mourad AI, Gniadecki R. Biologic drug survival in psoriasis: a systematic review & comparative meta-analysis. Front Med (Lausanne) Frontiers Media S A. 2021;18(7): 625755. doi: 10.3389/fmed.2020.625755. PMID: 33816514; PMCID: PMC8012481.
   Google Scholar
• Gao L, Li Q, Zhang H, et al. A biosimilarity study between QX001S and ustekinumab in healthy Chinese male subjects. Front Pharmacol. 2021;12:12. doi: 10.3389/fphar.2021.675358
   Web of Science ®Google Scholar
• Journal Editor G, Generics and Biosimilars Initiative Journalournal Editor. Patent expiry dates for biologicals: 2018 update. GaBi J. 2019;8(1):24–31. doi: 10.5639/gabij.2019.0801.003
   Google Scholar
• Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–130. doi: 10.1084/jem.20030451
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Papp KA, Lynde CW. Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111–1119. doi: 10.1111/jdv.14868
   PubMed Web of Science ®Google Scholar
• Ilumetri -Tildrakizumab. European Medicines Agency (EMA). 2023.
   Google Scholar
• Tremfya - Guselkumab. European Medicines Agency (EMA). 2022.
   Google Scholar
• Skyrizi - Risankizumab. European Medicines Agency (EMA). 2022.
   Google Scholar
• Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021;22(2):173–192. doi: 10.1007/s40257-020-00578-0
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Camela E, et al. A case of erythrodermic psoriasis successfully treated with guselkumab. Dermatol Ther. 2020;33(2): doi: 10.1111/dth.13238
   Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. doi: 10.1016/j.jaad.2016.11.041
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431. doi: 10.1016/j.jaad.2016.11.042
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–839. doi: 10.1016/S0140-6736(19)31773-8
   PubMed Web of Science ®Google Scholar
• Langley RG, Tsai T-F, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123. InternetAvailable from. doi: 10.1111/bjd.15750
   PubMed Web of Science ®Google Scholar
• Mälkönen T, Nuutinen P, Hallinen T, et al. Guselkumab treatment outcomes and persistence in a nationwide real-world cohort of patients with plaque psoriasis. Acta Derm Venereol. 2022;102:adv00631. doi: 10.2340/actadv.v101.910
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9(7):2170. doi: 10.3390/jcm9072170
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, et al. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatological Treat. 2022;33(5):2560–2564. doi: 10.1080/09546634.2022.2036674
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Malagoli P, et al. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol. 2023;37(5):1017–1027. doi: 10.1111/jdv.18913
   PubMed Web of Science ®Google Scholar
• Iznardo H, Vilarrasa E, López-Ferrer A, et al. Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. Br J Dermatol. 2021;185(3):660–662. John Wiley and Sons Inc. doi: 10.1111/bjd.20416
   PubMed Web of Science ®Google Scholar
• Ruiz‐Villaverde R, Rodriguez‐Fernandez‐Freire L, Armario‐Hita JC, et al. Guselkumab: mid‐term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther. 2021;34(2): doi: 10.1111/dth.14798
   Web of Science ®Google Scholar
• Gerdes S, Asadullah K, Hoffmann M, et al. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab. J Eur Acad Dermatol Venereol. 2022;36(9):1568–1577. doi: 10.1111/jdv.18218
   PubMed Web of Science ®Google Scholar
• Del Alcázar E, López-Ferrer A, Á M-D, et al. Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish psoriasis group. J Dermatological Treat. 2022;33(6):2878–2880. doi: 10.1080/09546634.2022.2079596
   PubMed Web of Science ®Google Scholar
• Hugo J, Kojanova M, Turkova B, et al. Long-term efficacy, safety, and drug survival of guselkumab in patients with psoriasis: real-world data from the Czech Republic BIOREP registry. Dermatol Ther (Heidelb). 2023;13(3):787–801. doi: 10.1007/s13555-023-00893-4
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltImma-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661. doi: 10.1016/S0140-6736(18)31713-6
   PubMed Web of Science ®Google Scholar
• Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial 2021;184:p. 50–59
   Google Scholar
• Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–586. doi: 10.1016/S0140-6736(19)30952-3
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288. doi: 10.1016/S0140-6736(17)31279-5
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, et al. Risankizumab treatment in psoriasis patients who failed anti‐IL17: a 52‐week real‐life study. Dermatol Ther. 2022;35(7): doi: 10.1111/dth.15524
   Web of Science ®Google Scholar
• Becher G, Conner S, Ingram JA, et al. A retrospective real-world study of the effectiveness and tolerability of tildrakizumab in UK adults with moderate-to-severe chronic plaque psoriasis. Dermatol Ther (Heidelb). 2022;12(10):2343–2354. doi: 10.1007/s13555-022-00800-3
   PubMed Web of Science ®Google Scholar
• Graier T, Weger W, Jonak C, et al. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian psoriasis registry (PsoRA). Sci Rep. 2022;12(1):15078. doi: 10.1038/s41598-022-18790-9
   PubMed Web of Science ®Google Scholar
• Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatological Treat. 2023;34(1). doi: 10.1080/09546634.2022.2133531
   PubMed Web of Science ®Google Scholar
• Lytvyn Y, Zaaroura H, Mufti A, et al. Drug survival of guselkumab in patients with plaque psoriasis: a 2 year retrospective, multicenter study. JAAD Int. 2021;4:49–51. doi: 10.1016/j.jdin.2021.05.003
   PubMedGoogle Scholar
• Egeberg A, Rosenø NAL, Aagaard D, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - a nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979. doi: 10.1016/j.semarthrit.2022.151979
   PubMed Web of Science ®Google Scholar
• Cosentyx - Secukinumab. European Medicines Agency (EMA). 2022.
   Google Scholar
• Taltz - Ixekizumab. European Medicines Agency (EMA). 2023.
   Google Scholar
• Kyntheum - Brodalumab. European Medicines Agency (EMA). 2023.
   Google Scholar
• Bimzelx - Bimekizumab. European Medicines Agency (EMA). 2022.
   Google Scholar
• Freitas E, Blauvelt A, Torres T. Bimekizumab for the treatment of psoriasis. Drugs. 2021;81(15):1751–1762. doi: 10.1007/s40265-021-01612-z
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi: 10.1056/NEJMoa1314258
   PubMed Web of Science ®Google Scholar
• Azevedo A, Torres T. Eficacia y seguridad clínica del ixekizumab para el tratamiento de la psoriasis. Actas Dermo-Sifiliográficas. 2017;108(4):305–314. doi: 10.1016/j.ad.2016.09.021
   PubMed Web of Science ®Google Scholar
• Russell CB, Rand H, Bigler J, et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti–IL-17 receptor monoclonal antibody. J Immunol. 2014;192(8):3828–3836. doi: 10.4049/jimmunol.1301737
   PubMed Web of Science ®Google Scholar
• Notario J, Deza G, Vilarrasa E, et al. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. J Dermatological Treat. 2019;30(5):424–429. doi: 10.1080/09546634.2018.1528000
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Ighani A, Phung M, et al. Drug survival of secukinumab in real-world plaque psoriasis patients: a 52-week, multicenter, retrospective study. J Am Acad Dermatol. 2018;78(5):1019–1020. doi: 10.1016/j.jaad.2017.11.036
   PubMed Web of Science ®Google Scholar
• Torres T, Balato A, Conrad C, et al. Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study. J Am Acad Dermatol. 2019;81(1):273–275. doi: 10.1016/j.jaad.2019.02.031
   PubMed Web of Science ®Google Scholar
• Lee EB, Amin M, Egeberg A, et al. Drug survival of secukinumab for psoriasis in a real-world setting. J Dermatological Treat Taylor And Francis Ltd. 2019;30(2):150–151. doi: 10.1080/09546634.2018.1473838
   PubMed Web of Science ®Google Scholar
• Foley P, Manuelpillai N, Dolianitis C, et al. Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study). Australas J Dermatol. 2022;63(3):303–311. doi: 10.1111/ajd.13895
   PubMed Web of Science ®Google Scholar
• Rompoti N, Sidiropoulou P, Panagakis P, et al. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. J Eur Acad Dermatol Venereol. 2020;34(6):1240–1247. doi: 10.1111/jdv.16202
   PubMed Web of Science ®Google Scholar
• Palacios-García L, Gómez-de Castro C, Mir-Bonafé M, et al. Comment on “secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study”. J Am Acad Dermatol. 2019;81(3):e81–e82. doi: 10.1016/j.jaad.2019.04.072
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Torres TRT. Reply to: “comment on ‘secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study’”. J Am Acad Dermatol. 2019;81(3):e83. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/31112724
   PubMed Web of Science ®Google Scholar
• Rompoti N, Katsimbri P, Kokkalis G, et al. Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: a 104-week clinical study. Dermatol Ther. 2019;32(5):32. doi: 10.1111/dth.13006
   Web of Science ®Google Scholar
• Nguyen HT, Pham NTU, Tran TNA, et al. Long-term effectiveness and drug survival of secukinumab in Vietnamese patients with psoriasis: results from a retrospective ENHANCE study. Dermatol Ther (Heidelb). 2022;13(2):465–476. doi: 10.1007/s13555-022-00867-y
   PubMed Web of Science ®Google Scholar
• Augustin M, Sator PG, von Kiedrowski R, et al. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study. J Eur Acad Dermatol Venereol. 2022;36(10):1796–1804. doi: 10.1111/jdv.18329
   PubMed Web of Science ®Google Scholar
• Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Galán-Gutierrez M, et al. Drug survival, discontinuation rates, and safety profile of secukinumab in real-world patients: a 152-week, multicenter, retrospective study. Int J Dermatol. 2020;59(5):633–639. doi: 10.1111/ijd.14819
   PubMed Web of Science ®Google Scholar
• Huang YYM, Ruth JS, Hsu S. Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks. J Am Acad Dermatol Mosby Inc. 2016;75(4):e169. doi: 10.1016/j.jaad.2016.05.049
   PubMed Web of Science ®Google Scholar
• Lee EB, Pithadia DJ, Reynolds KA, et al. Real-world drug survival of ixekizumab for psoriasis. J Am Acad Dermatol. 2019;81(1):270–272. InternetAvailable from. doi: 10.1016/j.jaad.2019.01.034
   PubMed Web of Science ®Google Scholar
• Reich A, Reed C, Schuster C, et al. Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021. J Dermatological Treat. 2023;34(1): doi: 10.1080/09546634.2022.2160196
   Web of Science ®Google Scholar
• Öğüt N D, Yıldırım S K, Erbağcı E, et al. Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting. J Of Cosmetic Dermatology. 2022;21(11):6215–6224. doi: 10.1111/jocd.15217
   PubMed Web of Science ®Google Scholar
• Malagoli P, Dapavo P, Pavia G, et al. Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: a 192 weeks multicentric retrospective study—IL PSO (Italian landscape psoriasis). Dermatol Ther. 2022;35(8): doi: 10.1111/dth.15608
   Web of Science ®Google Scholar
• Gulliver W, Gooderham MJ, Zhu B, et al. Treatment persistence of ixekizumab in adults with moderate-to-severe plaque psoriasis participating in the Canadian patient support program. Dermatol Ther (Heidelb). 2023;13(1):235–244. doi: 10.1007/s13555-022-00853-4
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L, Vender R, et al. Drug survival of interleukin (IL)‑17 and IL‑23 inhibitors for the treatment of psoriasis: a retrospective multi‑country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891–904. doi: 10.1007/s40257-022-00722-y
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Angelakopoulos C, Apalla Z, et al. Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: results from an interim analysis of the BrIDGE study. Dermatol Ther. 2022;35(12): doi: 10.1111/dth.15886
   Web of Science ®Google Scholar
• Rompoti N, Politou M, Stefanaki I, et al. Brodalumab in plaque psoriasis: real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks. J Eur Acad Dermatol Venereol. 2022;37(4):689–697. doi: 10.1111/jdv.18825
   Web of Science ®Google Scholar
• Kojanova M, Hugo J, Velackova B, et al. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry. J Dermatological Treat. 2022;33(6):2827–2837. doi: 10.1080/09546634.2022.2082354
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Malagoli P, et al. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis). Front Med. 2023;10:10. doi: 10.3389/fmed.2023.1196966
   Web of Science ®Google Scholar
• Ohata C, Ohyama B, Katayama E, et al. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: a single-center experience. J Dermatol. 2020;47(4):405–408. doi: 10.1111/1346-8138.15247
   PubMed Web of Science ®Google Scholar
• Cariti C, Dapavo P, Mastorino L, et al. Comparison of secukinumab and ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients. J Eur Acad Dermatol Venereol. 2022;36(3):e233–e235. InternetAvailable from. doi: 10.1111/jdv.17766
   PubMed Web of Science ®Google Scholar
• Leonardi C, Zhu B, Malatestinic WN, et al. Real-world biologic adherence, persistence, and monotherapy comparisons in US patients with psoriasis: results from IBM MarketScan® databases. Adv Ther. 2022;39(7):3214–3224. doi: 10.1007/s12325-022-02155-9
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Shi N, Burge R, et al. Comparison of real-world treatment patterns among biologic-experienced patients with psoriasis treated with ixekizumab or secukinumab over 18 months. Dermatol Ther (Heidelb). 2021;11(6):2133–2145. doi: 10.1007/s13555-021-00627-4
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Shi N, Somani N, et al. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings. J Am Acad Dermatol. 2022;86(3):581–589. doi: 10.1016/j.jaad.2021.06.878
   PubMed Web of Science ®Google Scholar
• Lockshin B, Cronin A, Harrison RW, et al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the corrona psoriasis registry. Dermatol Ther. 2021;34(2): doi: 10.1111/dth.14808
   PubMed Web of Science ®Google Scholar
• Li Y, Lu JJ, Zhong XY, et al. Drug survival outcomes associated with the real-world use of ixekizumab, secukinumab, guselkumab, and adalimumab for the treatment of plaque psoriasis in China: a 52-week single-center retrospective study. Clin Cosmet Investig Dermatol. 2022;15:2245–2252. doi: 10.2147/CCID.S387759
   PubMed Web of Science ®Google Scholar
• Jung SW, Lim SH, Jeon JJ, et al. Comparison of the efficacy and safety of biologics (secukinumab, ustekinumab, and guselkumab) for the treatment of moderate-to-severe psoriasis: real-world data from a single Korean center. Biomedicines. 2022;10(5):10. doi: 10.3390/biomedicines10051058
   Web of Science ®Google Scholar
• Blauvelt A, Burge R, Gallo G, et al. A retrospective cohort analysis of treatment patterns over 1 year in patients with psoriasis treated with ixekizumab or guselkumab. Dermatol Ther (Heidelb). 2022;12(3):701–714. doi: 10.1007/s13555-022-00686-1
   PubMed Web of Science ®Google Scholar
• Graier T, Salmhofer W, Jonak C, et al. Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis. Br J Dermatol. 2021;184(6):1094–1105. doi: 10.1111/bjd.19701.
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Puig L, Romero IB, et al. Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 «Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo». Actas Dermosifiliogr. 2022;113(6):583–609. doi: 10.1016/j.ad.2022.01.024
   PubMedGoogle Scholar
• Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial. Br J Dermatol. 2021;184:50–59.
   PubMed Web of Science ®Google Scholar
• Reich K, AW A, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394:831–839.
   PubMed Web of Science ®Google Scholar
• Mehta H, Mashiko S, Angsana J, et al. Differential Changes in inflammatory Mononuclear Phagocyte and T-Cell Profiles within psoriatic skin during treatment with guselkumab vs Secukinumab. J Invest Dermatol. 2021;141(7):1707–1718 e9. doi: 10.1016/j.jid.2021.01.005
   PubMed Web of Science ®Google Scholar
• López-Sánchez C, Puig L. Guselkumab in the treatment of moderate-to-severe plaque psoriasis. ImmunoTher Future Med Ltd. 2020;12(6):355–371. doi: 10.2217/imt-2020-0040
   PubMed Web of Science ®Google Scholar
• Nedoszytko B, Lange M, Sokolowska-Wojdylo M, et al. The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: the treg role in skin diseases pathogenesis. Postepy Dermatol Alergol. 2017. p. 405–417. Termedia Publishing House Ltd
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Armstrong AW, Langley RG, et al. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. J Dermatological Treat. 2022;33(4):2317–2324. doi: 10.1080/09546634.2021.1959504
   PubMed Web of Science ®Google Scholar
• Eyerich K, Weisenseel P, Pinter A, et al. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 2021;11(9):e049822. doi: 10.1136/bmjopen-2021-049822
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Patel M, Li C, et al. Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States. J Dermatological Treat. 2023;34(1): doi: 10.1080/09546634.2023.2200870
   PubMed Web of Science ®Google Scholar